Tier 4 — mechanistic

ELDERDIET: Effect of a Low-Calorie Mediterranean Diet, Intermittent Fasting, and Natural Senolytics on Aging Markers in Participants With Low and High Vascular Risk

Ramon Estruch
ISRCTN trial registry record 2026

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Funded by Instituto de Salud Carlos III and Hospital Clínic de Barcelona, according to the registry.
Competing interests
No manuscript-level competing-interest statement is available for this ongoing registry study.

Study snapshot

DesignRandomized blinded placebo-controlled parallel-group trial.
ModelAdults in two age strata with low/moderate or high/very-high cardiovascular risk and no established cardiovascular disease.
SamplePlanned enrollment: 4,000 participants; approximately half assigned to the combined intervention.
InterventionCombined intervention: hypocaloric Mediterranean diet, 14/10 intermittent fasting and fisetin 20 mg/kg/day for two consecutive days each month. Control: hypocaloric Mediterranean diet plus placebo.
DurationAt least 2 years, planned January 2026 to January 2030.
EndpointsSenescent-cell burden; Inflammation; DNA methylation; Mitochondrial function; Subclinical cardiovascular disease; Physical function and frailty; Advanced glycation end-products

What the study showed, in plain terms

ELDERDIET is a large Spanish randomized trial testing a combined lifestyle-plus-fisetin intervention in 4,000 adults across age and cardiovascular-risk strata. The intervention adds intermittent fasting and monthly fisetin pulses to a hypocaloric Mediterranean diet.

The scale makes the trial important, but it does not isolate fisetin from intermittent fasting and the more intensive dietary program. Any eventual between-group benefit will therefore represent the combined intervention unless additional analyses can separate components. No outcome results are available yet.

Key findings

  • Planned enrollment is 4,000 participants.
  • Fisetin is dosed at 20 mg/kg/day for two consecutive days each month.
  • The intervention also includes intermittent fasting and a hypocaloric Mediterranean diet.
  • Primary research areas include cellular aging and subclinical cardiovascular disease.

What this study can and cannot tell us

  • No results available.
  • Combined intervention prevents clean fisetin-specific causal attribution.
  • Long duration means adherence to diet, fasting and supplement components may differ.
  • Registry protocol should not be interpreted as an established anti-aging treatment.

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology